VectorY Email Format
Biotechnology ResearchNorth Holland, Netherlands51-200 Employees
VectorY is a biotechnology company based in Amsterdam, North Holland, founded in August 2020, that develops therapies by combining antibodies with gene therapy to create long-lasting treatments for large disease areas with high unmet medical need. Its core focus is on vectorized antibodies and related gene therapy approaches for both central nervous system and somatic disorders, with a particular emphasis on muscle diseases. The company operates its research and manufacturing facilities in Amsterdam and aims to establish a state-of-the-art multi-product GMP facility in the Netherlands to support scalable production of AAV-based therapies. The manufacturing capability would include suspension-based AAV vector production at scales suitable for clinical and commercial supply. VectorY targets neurodegenerative disease programs and related conditions, pursuing durable, disease-modifying therapies through its vectorized antibody platform. A recent development includes a collaboration with Shape Therapeutics announced in September 2025 to pursue vectorized antibodies for neurodegenerative diseases using an AAV5-derived CNS capsid.